The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia)

81Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Congenital disorders of glycosylation are a clinically and genetically heterogeneous group of disorders resulting from abnormal glycosylation of various glycoconjugates. The first description of congenital disorders of glycosylation was published in the early 80s and once screening tests for glycosylation disorders (CDGs) became readily available, CDG-Ia became the most frequently diagnosed CDG subtype. CDG-Ia is pan-ethnic and the spectrum of the clinical manifestations is still evolving: it spans from severe hydrops fetalis and fetal loss to a (nearly) normal phenotype. However, the most common presentation in infancy is of a multisystem disorder with central nervous system involvement. © 2009 Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Grünewald, S. (2009, September). The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochimica et Biophysica Acta - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2009.01.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free